成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 75706-12-6 Chemical Structure| 75706-12-6
Chemical Structure| 75706-12-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 75706-12-6

,{[proInfo.pro_purity]}

Leflunomide is a dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 2.5 μM, it is a disease-modifying antirheumatic drug (DMARD) and inhibits de novo pyrimidine synthesis.

Synonyms: SU101; HWA486; Leflunomide, Arava, Leflunomidum, HWA-486

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Leflunomide

CAS No. :75706-12-6
Formula : C12H9F3N2O2
M.W : 270.21
SMILES Code : O=C(C1=C(C)ON=C1)NC2=CC=C(C(F)(F)F)C=C2
Synonyms :
SU101; HWA486; Leflunomide, Arava, Leflunomidum, HWA-486
MDL No. :MFCD00867593
InChI Key :VHOGYURTWQBHIL-UHFFFAOYSA-N
Pubchem ID :3899

Safety of Leflunomide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

In Vitro:

Cell Line
Concentration Treated Time Description Reference
C17.2 cells 50 μM 16 hours To evaluate whether Leflunomide could promote cell survival following OGD, and it was found that Leflunomide was unable to promote cell survival. PMC11011260
WRJ388 cells 36 μM (Day 2), 15 μM (Day 4) 2-4 days Suppressed the growth of WRJ388 cells, primarily through S-phase cell cycle arrest PMC7867620
4T1 cells 10 μM 3 days Leflunomide induced mitochondrial elongation by promoting Mfn2 expression and reducing Drp1 levels, and restricted the proliferative capacity of 4T1 cells. PMC11540020
hOAT1-HEK293 cells 5 μM 30 minutes To investigate the effect of teriflunomide on the uptake of acyclovir in hOAT1-HEK293 cells, results showed that teriflunomide significantly inhibited the uptake of acyclovir. PMC7470779
hOAT3-HEK293 cells 5 μM 30 minutes To investigate the effect of teriflunomide on the uptake of acyclovir in hOAT3-HEK293 cells, results showed that teriflunomide significantly inhibited the uptake of acyclovir. PMC7470779
HeLa cells 20-51 μM 3-6 days Induced apoptosis in HeLa cells, resulting in the regression of HeLa xenografts PMC7867620
HAP1 cells 4 μM 48 hours Reduced caspase 3 and 7 activity, increased cell viability PMC7062591
H460 cells 80.5 μM (48 hours), 27 μM (72 hours) 48-72 hours Induced G1 cell cycle arrest but not apoptosis in H460 cells, attenuated the growth of H460-derived xenografts PMC7867620
MRP2-MDCK cells 0.5 - 100 μM 60 minutes To investigate the effect of leflunomide/teriflunomide on the accumulation of acyclovir in MRP2-MDCK cells, results showed that teriflunomide dose-dependently increased the accumulation of acyclovir with an IC50 value of 4.91 μmol/L. PMC7470779
MM cell lines 30-150 μM 72 hours To validate the anti-MM activity of Leflunomide, results showed inhibition of MM cell growth. PMC6457239
HeLa cells 4 μM Validated leflunomide's inhibition of caspase 3/7 activity PMC7062591

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Zebrafish ttc7a mutant zebrafish Dissolved in water 4 μM 3 to 7 days Increased gut motility, reduced intestinal tract narrowing, increased intestinal cell survival PMC7062591
NOD/SCID/γchain null mice MM.1S cell xenograft model Oral 40 mg/kg Once daily, 5 days per week, continuous treatment To evaluate the effect of Leflunomide combined with Lenalidomide on survival in an MM model, results showed significantly prolonged survival with the combination treatment. PMC6457239
Mice Breast cancer model Oral 25 or 50 mg/kg 5 days on, 2 days off, throughout the duration of the experiment Leflunomide significantly reduced the number of visible metastatic lesions and total metastatic area in the lungs of the 4T1 breast cancer model. PMC11540020
Mice HeLa xenografts Oral 35 mg/kg/day Once daily for 21 days Resulted in the regression of HeLa xenografts PMC7867620

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03709446 Breast Neoplasms|Breast Diseas... More >>es|Metastatic Triple Negative Breast Cancer Less << PHASE1|PHASE2 RECRUITING 2025-10-26 Mt Sinai Chelesa, New York, Ne... More >>w York, 10011, United States|Mt Sinai West, New York, New York, 10019, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States Less <<
NCT04463615 Recurrent Lymphoproliferative ... More >>Disorder|Refractory Lymphoproliferative Disorder Less << PHASE2 COMPLETED 2021-07-28 City of Hope Medical Center, D... More >>uarte, California, 91010, United States Less <<
NCT00001863 Uveitis PHASE2 COMPLETED 2025-02-03 National Eye Institute (NEI), ... More >>Bethesda, Maryland, 20892, United States Less <<
NCT00001573 Glioma|Sarcoma PHASE1 COMPLETED 2000-05-01 National Cancer Institute (NCI... More >>), Bethesda, Maryland, 20892, United States Less <<
NCT04361214 COVID-19 PHASE1 TERMINATED 2022-01-31 University of Chicago, Chicago... More >>, Illinois, 60637, United States Less <<
NCT00563849 Rheumatoid Arthritis PHASE4 COMPLETED 2025-08-04 Sanofi-Aventis, Pusan, Korea, ... More >>Republic of Less <<
NCT00637819 Systemic Lupus Eythematosus (S... More >>LE) Less << PHASE2 COMPLETED 2025-07-04 Sanofi-Aventis, Hong Kong, Hon... More >>g Kong Less <<
NCT05937880 Henoch-Schonlein Purpura RECRUITING 2027-06-30 Sun Yat-sen Memorial Hospital,... More >> Sun Yat-sen University, Guangzhou, Guangdong, 510120, China Less <<
NCT00101374 HIV Infections PHASE1 COMPLETED 2008-05-21 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00280644 Arthritis, Rheumatoid PHASE4 COMPLETED - Sanofi-Aventis, Istanbul, Turk... More >>ey Less <<
NCT02024334 Juvenile Idiopathic Arthritis PHASE4 UNKNOWN 2025-12-14 Mashhad, Khorasan Razavi, Iran... More >>, Islamic Republic of Less <<
NCT06714461 Rheumatoid Arthritis|Psoriatic... More >> Arthritis Less << NOT_YET_RECRUITING 2025-07-01 Sanofi-Aventis, Chilly-Mazarin... More >>, 91380, France Less <<
NCT04997993 PTEN-null Advanced Solid Tumor... More >>s Less << PHASE1 RECRUITING 2025-09-26 Icahn School of Medicine at Mo... More >>unt Sinai, New York, New York, 10029, United States Less <<
NCT04212416 Chronic Graft Versus Host Dise... More >>ase|Steroid Refractory Graft Versus Host Disease Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-06-12 City of Hope Medical Center, D... More >>uarte, California, 91010, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.01mL

7.40mL

3.70mL

References

 

Historical Records

Categories